You are here:
NICE
NICE Guidance
Conditions and diseases
Cancer
Metastases
Docetaxel for the treatment of hormone-refractory metastatic prostate cancer
Technology appraisal guidance
Reference number:
TA101
Published:
28 June 2006
Guidance
Tools and resources
Information for the public
Evidence
History
Research recommendations coming out of this guidance
There are no research recommendations for TA101